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Abstract  29 
Our objective was to assess whether volatile organic compound (VOC) analysis of vaginal 30 
swabs can detect maternal Group B Streptococcus during pregnancy in a prospective 31 
exploratory study. 243 women attending a high risk antenatal clinic at one university teaching 32 
hospital in the UK consented to take part and provide vaginal swabs throughout pregnancy. 33 
VOC analysis of vaginal swabs was undertaken and compared with the reference standard of 34 
GBS detected using enrichment culture method. The chemical components that emanated 35 
from the vaginal swabs were measured by gas chromatograph ion mobility spectrometry (GC-36 
IMS). This platform has both high sensitivity and good specificity to a range of chemical 37 
compounds. Our main outcome was to determine the sensitivity and specificity of VOC 38 
analysis for the detection of maternal GBS in vaginal swabs during pregnancy. Our study has 39 
demonstrated that the sensitivity and specificity of the VOC analysis by GC–IMS for the 40 
detection of GBS from vaginal swabs was 0.81 (95% CI, 0.71-0.89) and 0.97 (95% CI, 0.91-1) 41 
respectively. We conclude that the use of VOCs as biomarkers for the detection of maternal 42 
GBS in the vagina is a novel tool. As this test produces results within minutes and is of low 43 
unit test cost it has the potential to be used in clinical settings, where fast diagnosis is 44 
important, for example, a patient in early labour.  45 
 4 
Main research article 46 
Introduction 47 
Group B Streptococcus (GBS) is the most frequent cause of life-threatening early onset 48 
infection in newborn infants in the UK, known as early-onset group B Streptococcus (EOGBS) 49 
disease [1]. The incidence of EOGBS in the UK in 2015 was 0.57/1000 births [2]. GBS commonly 50 
colonises the gastrointestinal and genital tract of adults, with a global mean prevalence of 51 
17%[3]. GBS only rarely causes disease in the immunocompromised adult, but it can pose a 52 
significant risk to newborn infants due to their immature immune systems.  53 
 54 
The optimal screening strategy to prevent EOGBS is uncertain. Internationally there is a 55 
variation in guidelines, the 2019 ACOG recommends screening between 36+0-37+6 weeks 56 
gestation [4] but in the UK, universal screening is not currently recommended [5]. Maternal 57 
colonisation with GBS is the primary risk factor for disease (transmission to newborns is 58 
4070% and of these 12% will develop infection) [6, 7]. UK guidelines advocate offering 59 
intrapartum antibiotics to women found to be colonised during pregnancy and to those with 60 
other risk factors as this reduces the risk of culture positive EOGBS disease in the neonate [1, 61 
8].  62 
 63 
However, GBS colonisation status can be persistent but also intermittent and therefore 64 
transient during pregnancy. Up to 13% of women who are GBS positive in the before 37 weeks 65 
gestation receive unnecessary prophylatic antibiotics during labour [9, 10], which may 66 
contribute to increasing antibiotic resistance. The previous universal screening policy in the 67 
United States tested women between 3537 weeks, studies of this had demonstrated that 68 
 5 
among women who had a negative screening, 210% will become colonised before the onset 69 
of labour[10, 11].  70 
 71 
The currently used diagnostic methods for colonisation with GBS utilise time-consuming 72 
enrichment culture methods (over 24 hours) [12] and therefore aren’t appropriate for an 73 
intrapartum scenario. However, this method maximises GBS identification in cultures and is 74 
therefore the recommended technique in current guidance [4, 12]. Ideally, we would be able 75 
to screen for GBS colonisation at the start of labour so that only those women colonised in 76 
labour would be given antibiotics. Hence, there is a need to develop an accurate point of care 77 
test, which produces results within a few minutes, to reduce the burden of EOGBS disease.  78 
 79 
An approach that could be applied to this medical need is to measure the volatile organic 80 
compounds (VOCs) that emanate from a vaginal sample. The concept of measuring VOCs for 81 
clinical applications is currently gaining momentum, with a broad range of biological materials 82 
and diseases being investigated. For example researchers have investigated diseases as 83 
diverse as colon cancer, pancreatic cancer, irritable bowel disease and respiratory tract 84 
infections in urine, stool, swabs and breath [13-16]. Such techniques hold considerable 85 
promise, as the test can be undertaken in a clinically relevant time period, the cost per test 86 
can be low and the instrument can be sited near or in the ward, thus ideal of point-of-care 87 
needs. The objective of this study was to determine the ability of VOC analysis to detect 88 
maternal GBS in vaginal swabs in pregnant women.  Meeting this objective involved 89 
comparing GBS detected on vaginal swabs using the enrichment culture method to VOCs 90 
analysed by GC-IMS (gas chromatography ion mobility spectrometry).  91 
 92 
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Material and Methods  93 
Study design 94 
We conducted a prospective exploratory study at one UK hospital (University Hospitals 95 
Coventry & Warwickshire) serving a diverse population. The study protocol was approved by 96 
the NHS Research Ethics Committee West Midlands Birmingham South on 14th January 2014 97 
(13/WM/0486) and all participants gave written informed consent. The Group B Strep 98 
Support charity were consulted prior to the application for funding regarding a patient 99 
perspective about the study. Research was carried out according to The Code of Ethics of the 100 
World Medical Association (Declaration of Helsinki). 101 
 102 
Participants and test methods 103 
From 25th January 2017, women between 1436 weeks gestation were consented during 104 
their attendance to a high risk antenatal clinic for women at an increased risk of spontaneous 105 
preterm birth. A speculum examination was performed as per patient routine care. No 106 
specific hygiene advice was given. As part of routine screening in the preterm prevention 107 
clinic, a vaginal swab (reference standard) for microbiology culture and sensitivity testing 108 
using the enriched culture method was taken and placed into a non-nutritive transport 109 
medium, and concurrently two cotton swabs were used to obtain index test vaginal samples. 110 
The index test swabs were then placed in a universal containers and snap frozen in liquid 111 
nitrogen and stored at 80C. Specimens were obtained by gently rotating the swabs across 112 
the mucosa of the vagina. Biomedical scientists independently interpreted the reference 113 
swab cultures. Demographic data including age at booking pregnancy, BMI, parity and 114 
ethnicity were collected about each woman (Table 1). Samples were taken in a consecutive 115 
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series from all women who consented in the clinic, some women consented to samples being 116 
taken during every attendance to the clinic.  117 
 118 
Chemical analyser  119 
Chemical vapour analysis of the index swabs was undertaken in the BioMedical Sensors 120 
Laboratory, School of Engineering, University of Warwick. Here a Gas Chromatograph-Ion 121 
Mobility Spectrometer (GC-IMS) was used. Our group have previously used this instrument 122 
on a range of medical conditions including respiratory tract infections, Coeliac’s disease and 123 
irritable bowel disease [16-18]. This instrument was chosen over more traditional gas 124 
chromatograph mass spectrometer (GCMS) as the basic sensitivity of the instrument is much 125 
higher than GCMS, it can use nitrogen/air as the carrier gas (so no need for expensive carrier 126 
gases such as helium), has a lower purchase/test cost than GCMS and has a much smaller 127 
form factor, making it applicable for a ward setting.  128 
 129 
The GC-IMS instrument used was manufactured by G.A.S. (GC-IMS is also the product name, 130 
Dortmund, Germany). In use the samples, in this case formed of a mixture of VOCs that 131 
emanate from the vaginal swab, are injected into the GC-IMS. These VOCs are preseparated 132 
by the gas chromatograph (GC) column, which takes the complex mix of chemicals and 133 
separates them based on their interaction with the long column coated with a rententive 134 
layer. Thus chemicals elude from the column at different times (known as the retention time). 135 
These pre-separated chemicals exit the GC and enter a drift tube ion mobility spectrometry 136 
(IMS) detector. Here the molecules are ionized using a radioactive source (in this case tritium) 137 
and then released into the drift tube in a controlled manner. The ions are then moved along 138 
the drift tube using an electric field. At the same time a buffer gas (nitrogen) is fed in the 139 
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opposite direction to the ions. The resultant impacts between the ions and the buffer gas 140 
reduce the velocity of the ions. Thus ions achieve different velocities due to its interaction 141 
with both the electric field and the buffer gas, which is inversely proportional to their size, 142 
mass and charge and then are collected on a Faraday plate, to provide a time-dependent 143 
signal corresponding with ion mobility. The device can measure substances in the low ppb 144 
range. The instrument was suitable for a clinical setting and was placed on a work surface 145 
(dimensions: 45 x 50 x 20 cm; mass: 20 kg). 146 
 147 
Chemical testing and analysis 148 
In total 607 samples from 243 women were tested using the G.A.S. GC-IMS system. Swabs 149 
were thawed and transferred to a 20ml glass vial in batches of 20. The vials were then sealed 150 
with a crimp top lid fitted with a PTFE septum. The index samples were then placed in a vial 151 
tray cooled and maintained at 4oC to reduced unwanted odour emission and sample 152 
degradation, whilst other samples were being tested. Prior to the sample measurement, 153 
samples were heated to 40oC for 10 minutes. The sample line for the GC-IMS was inserted 154 
into the septa of the vial using a needle and 2mls of sample were then extracted from the vial 155 
and injected into the analytical platform. The machine settings were as follows: E1: 150 156 
ml/min (for the drift tube IMS), E2: 20 ml/min (for the GC column) and the pump at 25%. The 157 
total run time was 10 minutes.  The temperatures were set to: T1: 45oC, T2: 80oC, and T3: 158 
70oC.  159 
 160 
Statistical analysis 161 
The data was analysed using the statistical pipeline successfully used in [16-18]. In summary, 162 
the GC-IMS data was first extracted using the L.A.V. software (v2.2.1, G.A.S, Germany), which 163 
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converts the data from its native file format to a text file. This was followed by a pre-164 
processing step to reduce the dimentionality of the data, making the statistical analysis less 165 
computationaly  intensive. A typical GC-IMS output file (of a single sample) contains typically 166 
11 million data points. Though the number of data points is high, the information content is 167 
sparse, with the all of the values containing non-background information being located 168 
around the centre of the dataset. Thus, we are able to crop the central section of the data 169 
and then apply a threshold to make the background values all be zero. These values are 170 
selected by visual inspection of the data using the LAV software and results in around a 500 171 
fold reduction in the number of non-zero data points. Once completed, the data was analysed 172 
using a 10-fold cross validation approach. In each fold, the data was split into a 90% training 173 
set and a 10% test set. Features with discriminary power were identified form the training set 174 
using a rank-sum test and 50 features with the lowest p-value were taken forward for 175 
classification. Here, five different classifiers we used, specifically sparse logistic regression, 176 
random forest, Gaussian process classifier, support vector machine and neural network (this 177 
set is commonly used within our pipeline). Once the training models had been created, they 178 
were applied to the same features in the test set. This process is repeated ten times until all 179 
the data has a test result. This process provided test probabilities for each sample and from 180 
this, statistical values, including sensitivity and specificity were calculated. 181 
 182 
Results 183 
Between January 2017 and August 2018, 243 women had vaginal swabs taken throughout 184 
pregnancy. The demographic data of these women shows the majority of women were white 185 
(79.0%) and two thirds were multiparous and one third nulliparous (Table 1). The maternal 186 
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GBS colonisation rates as defined by a positive enriched culture from vaginal swabs was 13.6% 187 
(corresponding to 33 women). 188 
 189 
Figure 1 shows a typical output of the GC-IMS to a positive swab. The background is 190 
represented in blue with the non-blue areas showing that the instrument is detecting 191 
chemicals. The intensity of the peak (with red being the highest intensity) represents the 192 
amount of ions (and thus the chemical) detected. In general, each of the circular areas of 193 
higher intensity represent a different chemical. Furthermore, it can be see that the majority 194 
of the reponse is in the central section of the output.  What was found is that the number of 195 
chemical peaks changed significantly across the cohort (independent of them being GBS 196 
positive or negative), which is likely to reflect vaginal biome, but were not investigated further 197 
in this study. The data from the G.A.S. GC-IMS was analysed as described and the statistical 198 
output is shown in Table 2. The high sensitivity and specificity indicates a strong signal is 199 
associated with GBS colonisation. The shape of the ROC curve illustrates the test has an 200 
excellent ability to discriminate between those with GBS from those without (Figure 2, Table 201 
2) To help visualise these differences, we have also created a box plot of the probabilities 202 
generated by the classifier for each sample, as shown in figure 3. The line in the centre of the 203 
box plot is the median and the upper/lower boundaries are the 25th and 75th percentiles and 204 
error bars defining the 10th and 90th percentiles. Data points outside this region are 205 
individually plotted as outliers. The plot shows that there are significant differences in the 206 
probabilities of GBS and non-GBS samples. 207 
 208 
Discussion  209 
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This is the first exploratory study to our knowledge to report the use of VOC analysis to detect 210 
GBS. In our prospective cohort study we investigated the potential of VOCs in the detection 211 
of GBS on vaginal swabs taken at the same time as samples for traditional GBS testing 212 
methods.  The ultimate aim is to be able to implement this technology as a point of care test 213 
for women intrapartum, reducing the incidence of EOGBS disease by appropriate 214 
administration of antibiotic prophylaxis.  215 
 216 
VOC profiles from vaginal swabs taken from pregnant women discriminated those whose 217 
swabs grow GBS from those who did not with a high sensitivity and specificity. Our results 218 
suggest that women who are colonised with GBS have chemically different vaginal swabs to 219 
those who are not colonised. The vagina has its own varied microbiome, but our data suggests 220 
that despite this, there are differences in VOCs from vaginal swabs in those who are colonised 221 
with enough GBS to be detected by the enriched culture method. These GBS associated 222 
differences in VOCs were demonstrated and are detectable with this novel technology.  The 223 
VOCs detected are believed to be the gaseous waste products produced from the metabolic 224 
pathways of the bacteria in the vaginal, which occur as a result of the complex interactions in 225 
the vagina between, the vaginal and cervical epithelial cells, the vagina flora and invading 226 
pathogens. False positive tests could be driven by alterations in either the vaginal flora or the 227 
maternal host response. This study suggests that GBS produces a unique VOC fingerprint in 228 
pregnancy. A recent meta-analysis of the VOC literature found that VOCs could differentiate 229 
11 other microbial pathogens in multiple disease states, but did not include the detection of 230 
GBS in pregnancy [19, 20].   231 
 232 
 12 
Our results demonstrate that the G.A.S. GC-IMS instrument has a very high specificity and 233 
negative predictive value for the detection of GBS in vaginal swabs. This technology could 234 
now be developed as a bedside test for GBS colonisation. Previous studies have demonstrated 235 
high patient acceptability for intrapartum testing for GBS [21]. In the acute intrapartum 236 
scenario, women could have a swab taken and analysed in a hand held device in minutes. 237 
Where the results are positive, this could guide clinicians to prompt and appropriate 238 
administration of intrapartum antibiotics, reducing the risk of EOGBS. This would reduce 239 
residual GBS disease as it would allow us to treat the 10% women who may be negative at 240 
screening but convert to positive by the time of labour. The high negative predictive value of 241 
the test could be used to counsel families about the low likelihood of colonisation with GBS 242 
and bring into question whether administration of antibiotic prophylaxis is necessary, 243 
reducing unnecessary antibiotic exposure to both the mother and infant. Furthermore, a large 244 
number of women need to be tested for a screening program and the cost of this test is 245 
minimal. 246 
 247 
Strengths of the study include the large number (n=607) of swabs analysed using the G.A.S. 248 
GC-IMS instrument and compared to the reference standard. We complied with the STARD 249 
statement and minimised bias as far as possible. However, there were a few limitations to our 250 
study. Our prevalence of colonisation with GBS is lower than expected at 13.6%, compared 251 
with the global average of 17.9% and European average 19.0% [3]. In the clinic women have 252 
a vaginal swab only (as part of their screening for risk of spontaneous preterm birth), this is 253 
not in keeping with recommendations for specimen collection for detection of colonisation 254 
of GBS. Swabbing both the lower vagina and rectum increases the culture yield when 255 
compared to sampling the vagina only [6, 22]. Previous studies sub-analysis has illustrated 256 
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that colonisation from low vaginal swabs only had a mean prevalence of 14.2%[3], this has 257 
more similarity to our cohort. In future studies we would aim to comply with the 258 
recommendations of a low vaginal and rectal swab to identify which women are colonised 259 
both for our reference and index test. Furthermore, we have not attempted to identify the 260 
specific biomarkers associated with GBS. This would require the use of a more sophisticated 261 
measurement platform (such as GCMS), which we were unable to undertake within this study. 262 
 263 
The Centre for Disease Control and Prevention recommend that in order to be considered 264 
clinically useful in the intrapartum period, a point of care test should have sensitivity and 265 
specificity equal to or greater than 90% [6]. It is possible that optimising our sample collection 266 
(for both the index and reference test) as recommended may further increase our sensitivity 267 
to reach this threshold. Furthermore, due to logistical issues, samples were not analysed on 268 
site and therefore had to be frozen and then transferred for analysis at a later date. This may 269 
have caused degradation of the VOCs and influenced the fingerprints obtained as has been 270 
shown in previous studies[23]. 271 
 272 
At present an optimal screening strategy to prevent EOGBS has not been established, the high 273 
specificity and sensitivity obtained in this study suggest that with further work, it could be 274 
possible to implement this type of technology into a clinically useful screening pathway. It 275 
would allow the timely initiation of therapeutics by clinicians to prevent EOGBS and 276 
furthermore prevent women and their babies unnecessarily remaining in hospital for 277 
observation and/or antibiotic administration to the neonate when not indicated. This type of 278 
analysis and use of VOCS as biomarkers has huge potential in medical diagnostics, VOCs are 279 
thought to reflect complex changes in the vagina and therefore this technology has the 280 
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potential to be utilised in the assessment of a variety of diseases in obstetrics and 281 
gynaecology.  282 
 283 
In conclusion, EOGBS disease remains the leading infectious cause of morbidity and mortality 284 
amongst neonates. Preventative efforts have reduced the burden of this disease over time 285 
but at present worldwide no universal screening tool or pathway can be agreed.  This study 286 
has shown that the VOC signature present in vaginal swabs of pregnant women distinguished 287 
those swabs from which GBS was detected.  Using the G.A.S. GC-IMS analytical platform with 288 
a sensitivity and specificity for GBS colonisation of 0.81 and 0.97 respectively. Development 289 
of this technology has the potential to provide clinically useful and cost-effective universal 290 
screening intrapartum for colonisation with GBS.  291 
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Table/Figure caption list 384 
Table 1: Demographic characteristics of the women taking part in the study, the booking BMI 385 
of six patients is not known. 386 
 387 
Table 2: Statistical output from G.A.S. GC-IMS analytical platform using a sparse logistic 388 
regression classifier. 389 
 390 
Figure 1: Typical output of the GC-IMS to a swab positive for GBS. The x axis represents the 391 
drift time of the IMS and the y axis the retention time of the same eluding out of the GC. The 392 
non-blue areas are chemical signals be detected by the instrument. 393 
 394 
Figure 2: ROC output for G.A.S. GC-IMS instrument for women colonised with GBS in 395 
pregnancy versus those who are not colonised 396 
 397 
Figure 3: The boxplot representing the distribution of level of probabilities of assigning VOC’S 398 
outputs, of patients with and without GBS using the classifiers described. The closer the 399 
probability is to 1, the more certainty the classification model has to define the sample group. 400 
The probability of assigning swabs to GBS positive or negative are clearly separated indicating 401 
high assurance of the classification model to classify the patient to the correct group.  402 
 403 
